Business
DECN Files Provisional Patent For GenViro! Professional COVID-19 :15 Swift Kit, Adds Enhanced Technology To Allow For Even Swifter Results
DECN Files Provisional Patent For GenViro! Professional COVID-19 :15 Swift Kit, Adds Enhanced Technology To Allow For Even Swifter Results.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"Company Adds A Second Impedance Channel To The GenViro! Test Strip, Correcting For Blood Hematocrit, Resulting In An Expected 30% Improvement In Reporting LOS ANGELES, CA / ACCESSWIRE / June 17, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc., today announced it has filed a provisional patent for its Genviro! Swift Professional product titled, "Method and Apparatus for Swift Determination of the Covid-19 Virus." In so doing, the company is unveiling its Hematocrit adjustment feature, initially developed for its GenUltimate TBG system. When incorporated into the GenViro! System an expected 30% improvement in result reporting time from the current testing time of :15 seconds will be available to the administrator of the test, while at the same time adjusting for issues involving an abundance of or insufficiency of red blood cells in a patient blood sample. The company will document this improvement in its previously announced FDA EUA Addendum II filing for PEUA200232. Pharma Tech Solutions first submitted its GenViro! professional use device to the FDA on April 3, 2020.Specifically, the addition of the Hematocrit (HCT) adjustment feature will be used during each testing phase of the GenViro! test kit, to adjust for an abundance of or insufficiency of red blood cells in a patient sample. The addition of our TBG technology will yield three benefits: 1) the exclusion of the need for a chemical lysing solution and its intricacies, 2) mathematically correct for the hematocrit effect, where high and low HCT has the potential to interfere with electronic readings, and 3) further lower the time required for a completed Covid-19 test result by an anticipated 30%.Such an addition makes the Covid-19 result virtually immediate. In fact, it will take longer to open the kit package and extract a GenViro! Swift test strip and draw a finger-tip drop of blood than it will to administer the test itself. The company expects its kit availability schedule to remain unchanged, with delivery outside the US commencing as early as during the summer months, and within the US and North American markets shortly after FDA authorization.Along with the provisional patent related to the test strip, the company will also be filing a second provisional patent for its GenUltimate TBG system under the ti...